TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01554189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match MK-8325 capsules, orally, once per day for 5 days
Study: NCT02804373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily during 28 days
Study: NCT02804373
Drug: Placebo continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration the following 2 days after each OXT administration, during 28 days.
Study: NCT04618744
Drug: ORMD-0801 (Insulin) capsule 8 mg BD
Normalized name: insulin, regular, human 8 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
Study: NCT01613495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Study: NCT01606969
Drug: scalp infiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
Study: NCT01606969
Drug: scalp infiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
Study: NCT02611817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab placebo-matching SC injection.
Study: NCT01315899
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given once as a single dose during the study as per Williams crossover design
Study: NCT02685306
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Study: NCT02942758
Drug: standard-dose AZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
Study: NCT00584012
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03874156
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
Study: NCT00088673
Drug: 3APS
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01764451
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03121807
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03121807
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02541500
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
Study: NCT02017704
Drug: capecitabine and IMRT (if randomized to this arm)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
Study: NCT02017704
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.
Study: NCT04329325
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Please see detailed summary.
Study: NCT05267938
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
Study: NCT00781404
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
Study: NCT00565006
Drug: MK0859
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03011775
Drug: Acetylsalicylic Acid 75Mg Tablet
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet per a day
Study: NCT03011775
Drug: Rosuvastatin Calcium 20 MG Oral Tablet
Normalized name: ROSUVASTATIN CALCIUM 20 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per a day
Study: NCT02993471
Drug: Drug Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01263444
Drug: Habitual prostaglandin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular therapy used daily as prescribed
Study: NCT00474006
Drug: arm II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
Study: NCT02228408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo titration will mimic titration of active study arm
Study: NCT05155839
Drug: MRG001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT01251991
Drug: Psyllium husks
Normalized name: Psyllium 500 MG Oral Capsule [PSYLLIUM HUSKS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study: NCT00227409
Drug: calcium disodium EDTA (edetate calcium disodium)
Normalized name: DISODIUM EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00931606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 4 subcutaneous doses of placebo given once every 28 days
Study: NCT02378688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00744692
Drug: Reduced Intensity Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03113994
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg Rosuvastatin, daily for 12 months
Study: NCT03113994
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily for 12 months
Study: NCT01512693
Drug: MK-0822
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
Study: NCT01620593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
Study: NCT03595189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour single intravenous administration
Study: NCT00741260
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine orally on days 1-14 of each 21 day cycle
Study: NCT05533073
Drug: A2: Etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
Study: NCT00035477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
Study: NCT01671891
Drug: capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
Study: NCT03355053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O.
Study: NCT02732249
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 30 min after morning and evening meals
Study: NCT00351806
Drug: Erigeron breviscapus injection
Normalized name: ERIGERON CANADENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00033371
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 400 mg PO twice a day
Study: NCT03571126
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
Study: NCT00808119
Drug: RTI-336 (CTDP 31862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
Study: NCT02608125
Drug: PRN1371
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01844427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01197794
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 twice daily
Study: NCT01197794
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 once daily
Study: NCT01197794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZD1981
Study: NCT00434278
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Study: NCT00043004
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00043004
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00043004
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02667730
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg four times daily for 7 days
Study: NCT02667730
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500mg twice daily for 7 days
Study: NCT02667730
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 100mg twice daily
Study: NCT02615262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride
Study: NCT01313039
Drug: AZ6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
Study: NCT01529450
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg (4 200-mg capsules/day) capsule
Study: NCT02399709
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02399709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00944801
Drug: Pegylated Liposomal Doxorubicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
Study: NCT01914939
Drug: placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00331084
Drug: antibiotic/steroid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gtt, 4x/day, 15 days
Study: NCT00648362
Drug: Amaryl® Tablets 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg, single dose fasting
Study: NCT02682147
Drug: Hypoxia administration study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: scan completed after 5 minutes of breathing in hypoxic air
Study: NCT02682147
Drug: Hyperoxia administration study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: scan completed after up to 15 minutes of breathing in hyperoxic air
Study: NCT02963766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03956550
Drug: REGN5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Dose every 4 weeks (Q4W)
Study: NCT03956550
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Dose every 4 weeks (QW4)
Study: NCT04198480
Drug: JMT103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
Study: NCT00237497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets, orally, once daily for up to 28 nights.
Study: NCT00318799
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Study: NCT02822898
Drug: NaCl 0.9% in Glucose 5% with 40mEq Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
Study: NCT02822898
Drug: Glucion 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
Study: NCT00440284
Drug: conventional vs. flexible, intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02186405
Drug: LEVOTHYROXINE
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of levothyroxine
Study: NCT03315507
Drug: PB1046 Subcutaneous Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight weekly doses of PB1046.
Study: NCT03366974
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bid
Study: NCT01466127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched nasal spray placebo
Study: NCT00767299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO, 24 weeks
Study: NCT02128724
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
Study: NCT03435276
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
Study: NCT00348491
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03021590
Drug: Clarithromycin 500Mg Oral Tablet
Normalized name: Clarithromycin 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth
Study: NCT00678795
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours
Study: NCT00678795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
Study: NCT04107805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01304394
Drug: Ped3CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
Study: NCT01852604
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC647055 will be supplied as 150 mg oral capsules.
Study: NCT02802930
Drug: SPF 50 Y65 110 (BAY987519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study: NCT02802930
Drug: SPF 50 Y51 002 (BAY987519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study: NCT02802930
Drug: SPF 15 V27 104 (BAY987519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study: NCT04673461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
Study: NCT03661125
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
Study: NCT02031939
Drug: Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
Study: NCT00986440
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017
Study: NCT00986440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00080496
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003000
Drug: fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01574261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for four months
Study: NCT01574261
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol 4g/die for four months
Study: NCT03506113
Drug: Guidelines-based antibiotics choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
Study: NCT03494296
Drug: patients received D-COP regimen chemotherapy
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received D-COP regimen chemotherapy
Study: NCT02286999
Drug: B. infantis
Normalized name: L. crispatus,gasseri,jensenii,rhamnosus/B. infantis 6 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
Study: NCT02286999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01934829
Drug: urea-based cream
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator.
Study: NCT00796224
Drug: 60 mg/kg azithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects taken 60 mg/kg azithromycin ER
Study: NCT00796224
Drug: 30 mg/kg azithromycin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects taken 30 mg/kg azithromycin IR (Immediate Release)
Study: NCT01786434
Drug: Fentanyl on-demand arm
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
Study: NCT00404794
Drug: prednisolone and mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00404794
Drug: prednisolone and tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01860833
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: time of treatment 14 days